Search

Your search keyword '"Matsuo, Mioko"' showing total 198 results
Start Over Author "Matsuo, Mioko"
198 results on '"Matsuo, Mioko"'

1. Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan

Author

Tsuchihashi, Kenji, Ito, Mamoru, Arita, Shuji, Kusaba, Hitoshi, Kusano, Wataru, Matsumura, Takashi, Kitazono, Takafumi, Ueno, Shohei, Taguchi, Ryosuke, Yoshihiro, Tomoyasu, Doi, Yasuhiro, Arimizu, Kohei, Ohmura, Hirofumi, Kajitani, Tatsuhiro, Nio, Kenta, Nakano, Michitaka, Oshima, Kotoe, Tamura, Shingo, Shirakawa, Tsuyoshi, Shimokawa, Hozumi, Uchino, Keita, Hanamura, Fumiyasu, Okumura, Yuta, Komoda, Masato, Isobe, Taichi, Ariyama, Hiroshi, Esaki, Taito, Hashimoto, Kazuki, Komune, Noritaka, Matsuo, Mioko, Matsumoto, Keiji, Asai, Kaori, Yoshitake, Tadamasa, Yamamoto, Hidetaka, Oda, Yoshinao, Akashi, Koichi, and Baba, Eishi

Published
2023
Full Text
View/download PDF

5. Correction: Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter clinical study

Author

WakasakiI, Takahiro, primary, Manako, Tomomi, additional, YasumatsuI, Ryuji, additional, Hara, Hirotaka, additional, Toh, Satoshi, additional, Masuda, Muneyuki, additional, YamauchiID, Moriyasu, additional, Kuratomi, Yuichiro, additional, Nishimura, Emi, additional, Takeuchi, Toranoshin, additional, Matsuo, Mioko, additional, Jiromaru, Rina, additional, Hashimoto, Kazuki, additional, Komune, Noritaka, additional, and Nakagawa, Takashi, additional

Published
2024
Full Text
View/download PDF

11. Progression-Free Survival and Treatment-Free Interval in Head and Neck Cancer with Long-Term Response to Nivolumab: Timing of Active Discontinuation.

Author

Matsuo, Mioko, Masuda, Muneyuki, Yamauchi, Moriyasu, Hashimoto, Kazuki, Kogo, Ryunosuke, Sato, Masanobu, Masuda, Shogo, and Nakagawa, Takashi

Subjects
*HEAD & neck cancer, *TERMINATION of treatment, *TREATMENT effectiveness, *DESCRIPTIVE statistics, *RETROSPECTIVE studies, *TREATMENT duration, *IMMUNE checkpoint inhibitors, *MEDICAL records, *ACQUISITION of data, *NIVOLUMAB, *PROGRESSION-free survival, *DISEASE relapse, *EVALUATION
Abstract

Simple Summary: This retrospective study aimed to determine the optimal timing of active discontinuation of long-term responders to immune checkpoint inhibitors in patients with recurrent/metastatic head and neck squamous cell carcinoma. We analyzed treatment duration and treatment-free interval (TFI) in 227 nivolumab-treated patients and determined the timing when progression-free survival (PFS) leveled off and when patients discontinued for unplanned reasons (toxicity or patient decision). The 3-year and 6-year PFS was 15.9% and 15.3%, respectively. The PFS curve was completely flat at 3 years. The median time for patients to request discontinuation was 36.8 months, with a median TFI of 15.1 months. The median time for discontinuation due to toxicity was 18.9 months, with a median TFI of 30.6 months. Given that the PFS curve completely leveled off at 3 years and the median time of discontinuation at the patient's choice was 3 years, we suggest considering treatment completion at 3 years. The optimal timing for actively discontinuing immune checkpoint inhibitor therapy in long-term responders with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains unresolved. We conducted a retrospective study of 246 patients with R/M HNSCC treated with nivolumab to determine the optimal timing to actively discontinue nivolumab therapy. We examined the point at which progression-free survival (PFS) plateaued in all cases. We compared the prognosis of 19 (7.7%) ongoing cases and 227 (92.3%) discontinued cases and analyzed treatment duration and treatment-free interval (TFI). The 6-year overall survival was 11.8% (median, 12.1), and the 6-year PFS was 15.3% (median, 3.0). The PFS curve remained stable for 3 years. The median duration of nivolumab treatment was 2.9 months (range 0.03–81.9): Ongoing group, 41.8 (5.6–81.9); Decision group, 36.8 (4.0–70.1); Toxicity group, 30.6 (2.8–64.8); and progressive disease group, 2.0 (0.03–42.9). TFI in the Decision group was 15.1 months (0.6–61.6) and 30.6 months (2.8–64.8) in the Toxicity group. Long-term responses in R/M HNSCC patients treated with nivolumab are rare but gradually increasing. For this patient group, our best estimate of the optimal time to end treatment is 3 years, as the PFS in this study reached a plateau at that timepoint. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Lacrimal Sac Tumors: A Single-institution Experience, Including New Insights

Author

WAKASAKI, TAKAHIRO, YASUMATSU, RYUJI, TANABE, MIKA, YOSHIKAWA, HIROSHI, JIROMARU, RINA, HASHIMOTO, KAZUKI, MATSUO, MIOKO, FUJIMURA, AKIKO, and NAKAGAWA, TAKASHI

Subjects
Pharmacology, Cancer Research, General Biochemistry, Genetics and Molecular Biology, Research Article
Abstract

Background/Aim: Lacrimal sac tumors are rare tumor types, with a long time interval from disease onset to diagnosis. We aimed to investigate the characteristics and outcomes of patients with lacrimal sac tumors. Patients and Methods: The medical records of 25 patients with lacrimal sac tumors initially treated at the Kyushu university hospital from January 1996 to July 2020 were reviewed. Results: Our analysis included 3 epithelial benign tumors (12.0%) and 22 malignant (88.0%) tumors (squamous cell carcinoma, n=6; adenoid cystic carcinoma, n=2; sebaceous adenocarcinoma, n=2; mucoepidermoid carcinoma, n=1; malignant lymphoma, n=10). The average time from symptom onset to diagnosis was 14.7 months (median=8 months; range=1-96 months). The analysis of patients revealed that lacrimal sac mass (22/25, 88.0%) was the most frequent symptom and a possible tumor marker. Most epithelial benign (n=3) and malignant epithelial (n=12) tumors were treated surgically (14/15, 93.3%). One malignant case was treated with heavy ion beam therapy. Eight patients were treated with postoperative (chemo)radiation therapy because of positive surgical margins (including one unanalyzed case). Local control was ultimately achieved in all but one case. The patient survived for 24 months with immune checkpoint inhibitors and subsequent chemotherapy for local and metastatic recurrence. Conclusion: We report our experience in the diagnosis and treatment of lacrimal sac tumors and analyze the clinical trends in cases involving these tumors. Postoperative radiotherapy and pharmacotherapy, including immune checkpoint inhibitors, may be useful for recurrent cases.

Published
2023
Full Text
View/download PDF

15. Adult head and neck para-meningeal rhabdomyosarcoma: survival outcomes including salvage therapy

Author

Tsuchihashi, Kenji, primary, Ito, Mamoru, additional, Arita, Shuji, additional, Kusaba, Hitoshi, additional, Kusano, Wataru, additional, Ueno, Shohei, additional, Taguchi, Ryosuke, additional, Yoshihiro, Tomoyasu, additional, Doi, Yasuhiro, additional, Ohmura, Hirofumi, additional, Kajitani, Tatsuhiro, additional, Nio, Kenta, additional, Nakano, Michitaka, additional, Oshima, Kotoe, additional, Tamura, Shingo, additional, Shirakawa, Tsuyoshi, additional, Shimokawa, Hozumi, additional, Uchino, Keita, additional, Hanamura, Fumiyasu, additional, Okumura, Yuta, additional, Komoda, Masato, additional, Isobe, Taichi, additional, Ariyama, Hiroshi, additional, Esaki, Taito, additional, Hashimoto, Kazuki, additional, Komune, Noritaka, additional, Matsuo, Mioko, additional, Matsumoto, Keiji, additional, Asai, Kaori, additional, Yoshitake, Tadamasa, additional, Yamamoto, Hidetaka, additional, Oda, Yoshinao, additional, Akashi, Koichi, additional, and Baba, Eishi, additional

Published
2023
Full Text
View/download PDF

22. Clinical Management of Early-Stage Hypopharyngeal Squamous Cell Carcinoma: A Single-Institution Clinical Analysis.

Author

Yasumatsu, Ryuji, Manako, Tomomi, Jiromaru, Rina, Hashimoto, Kazuki, Wakasaki, Takahiro, Matsuo, Mioko, and Nakagawa, Takashi

Subjects
HEAD & neck cancer diagnosis, HEAD & neck cancer treatment, LARYNGEAL tumors, HEAD & neck cancer, RETROSPECTIVE studies, EARLY detection of cancer, TUMOR classification, CANCER patients, SURVIVAL rate, TREATMENT effectiveness, DESCRIPTIVE statistics, RESEARCH funding, ENDOSCOPIC gastrointestinal surgery, SQUAMOUS cell carcinoma, HYPOPHARYNGEAL cancer, DISEASE management, DISEASE complications
Abstract

Objective: Early detection of hypopharyngeal squamous cell carcinoma (SCC) is important for both an improved prognosis and less-invasive treatment. We retrospectively analyzed the detection rates of early hypopharyngeal SCCs according to the evaluation methods and the clinical management of early hypopharyngeal SCCs. Methods: Sixty-eight patients with early hypopharyngeal SCC who were diagnosed were reviewed. Results: The number of early hypopharyngeal cancer patients with asymptomatic or synchronous or metachronous esophageal cancer examined by upper gastrointestinal endoscopy with narrow-band imaging (NBI) was significantly higher than those examined by laryngopharyngeal endoscopy with NBI. The 3-year disease-specific survival rates according to T classification were as follows: Tis, 100%; T1, 100%; T2, 79.8%; and overall, 91.2%, respectively. Conclusions: Early-stage hypopharyngeal SCC can be cured by minimally invasive transoral surgery or radiotherapy. Observation of the pharynx using NBI in patients with a history of head and neck cancer, esophageal cancer, gastric cancer, or pharyngeal discomfort is very important, and routinely examining the pharynx with NBI, even in patients undergoing endoscopy for screening purposes, is recommended. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study

Author

Wakasaki, Takahiro, primary, Manako, Tomomi, additional, Yasumatsu, Ryuji, additional, Hara, Hirotaka, additional, Toh, Satoshi, additional, Masuda, Muneyuki, additional, Yamauchi, Moriyasu, additional, Kuratomi, Yuichiro, additional, Nishimura, Emi, additional, Takeuchi, Toranoshin, additional, Matsuo, Mioko, additional, Jiromaru, Rina, additional, Hashimoto, Kazuki, additional, Komune, Noritaka, additional, and Nakagawa, Takashi, additional

Published
2022
Full Text
View/download PDF

24. Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study

Author

NAKANO, TAKAFUMI, primary, YASUMATSU, RYUJI, additional, HASHIMOTO, KAZUKI, additional, KUGA, RYOSUKE, additional, HONGO, TAKAHIRO, additional, YAMAMOTO, HIDETAKA, additional, MATSUO, MIOKO, additional, WAKASAKI, TAKAHIRO, additional, JIROMARU, RINA, additional, MANAKO, TOMOMI, additional, TOH, SATOSHI, additional, MASUDA, MUNEYUKI, additional, YAMAUCHI, MORIYASU, additional, KURATOMI, YUICHIRO, additional, TAURA, MASAHIKO, additional, TAKEUCHI, TORANOSHIN, additional, and NAKAGAWA, TAKASHI, additional

Published
2022
Full Text
View/download PDF

25. Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma

Author

HASHIMOTO, KAZUKI, primary, YASUMATSU, RYUJI, additional, KUGA, RYOSUKE, additional, HONGO, TAKAHIRO, additional, YAMAMOTO, HIDETAKA, additional, MATSUO, MIOKO, additional, WAKASAKI, TAKAHIRO, additional, JIROMARU, RINA, additional, MANAKO, TOMOMI, additional, TOH, SATOSHI, additional, MASUDA, MUNEYUKI, additional, YAMAUCHI, MORIYASU, additional, KURATOMI, YUICHIRO, additional, URYU, HIDEOKI, additional, NAKASHIMA, TORAHIKO, additional, TAMAE, AKIHIRO, additional, TANAKA, RISA, additional, TAURA, MASAHIKO, additional, TAKEUCHI, TORANOSHIN, additional, YOSHIDA, TAKAMASA, additional, and NAKAGAWA, TAKASHI, additional

Published
2022
Full Text
View/download PDF

26. Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer

Author

NAKANO, TAKAFUMI, primary, YASUMATSU, RYUJI, additional, HASHIMOTO, KAZUKI, additional, KUGA, RYOSUKE, additional, HONGO, TAKAHIRO, additional, YAMAMOTO, HIDETAKA, additional, MATSUO, MIOKO, additional, WAKASAKI, TAKAHIRO, additional, JIROMARU, RINA, additional, MANAKO, TOMOMI, additional, TOH, SATOSHI, additional, MASUDA, MUNEYUKI, additional, YAMAUCHI, MORIYASU, additional, KURATOMI, YUICHIRO, additional, URYU, HIDEOKI, additional, NAKASHIMA, TORAHIKO, additional, TAMAE, AKIHIRO, additional, TANAKA, RISA, additional, TAURA, MASAHIKO, additional, TAKEUCHI, TORANOSHIN, additional, YOSHIDA, TAKAMASA, additional, and NAKAGAWA, TAKASHI, additional

Published
2022
Full Text
View/download PDF

31. Association Between Immune-Related Hypothyroidism and Survival Outcomes in Patients with Head and Neck Cancer Treated with Nivolumab

Author

Hata, Kojiro, primary, Sasaki, Keiichi, additional, Watanabe, Hiroyuki, additional, Ikeda, Munehiko, additional, Tsuji, Toshikazu, additional, Ishida, Shigeru, additional, Ikebe, Mio, additional, Kumagai, Ayako, additional, Ozawa, Nana, additional, Matsukane, Ryosuke, additional, Nagata, Kenichiro, additional, Suetsugu, Kimitaka, additional, Tajima, Soichiro, additional, Yamada, Takaaki, additional, Egashira, Nobuaki, additional, Matsuo, Mioko, additional, Yasumatsu, Ryuji, additional, Nakagawa, Takashi, additional, and Ieiri, Ichiro, additional

Published
2021
Full Text
View/download PDF

35. Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events

Author

Yasumatsu, Ryuji, primary, Matsuo, Mioko, additional, Wakasaki, Takahiro, additional, Masuda, Muneyuki, additional, Takeuchi, Toranoshin, additional, Manako, Tomomi, additional, Jiromaru, Rina, additional, Uchi, Ryutaro, additional, Hashimoto, Kazuki, additional, and Nakagawa, Takashi, additional

Published
2020
Full Text
View/download PDF

36. Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Author

Wakasaki, Takahiro, primary, Yasumatsu, Ryuji, additional, Masuda, Muneyuki, additional, Takeuchi, Toranoshin, additional, Manako, Tomomi, additional, Matsuo, Mioko, additional, Jiromaru, Rina, additional, Uchi, Ryutaro, additional, Komune, Noritaka, additional, Noda, Teppei, additional, and Nakagawa, Takashi, additional

Published
2020
Full Text
View/download PDF

44. Table_1s20190420 – Supplemental material for Small Cell Carcinoma in the Head and Neck

Author

Wakasaki, Takahiro, Yasumatsu, Ryuji, Muneyuki Masuda, Matsuo, Mioko, Tamae, Akihiro, Kubo, Kazuhiko, Kogo, Ryunosuke, Uchi, Ryutaro, Taura, Masahiko, and Nakagawa, Takashi

Subjects
110315 Otorhinolaryngology, FOS: Clinical medicine
Abstract

Supplemental material, Table_1s20190420 for Small Cell Carcinoma in the Head and Neck by Takahiro Wakasaki, Ryuji Yasumatsu, Muneyuki Masuda, Mioko Matsuo, Akihiro Tamae, Kazuhiko Kubo, Ryunosuke Kogo, Ryutaro Uchi, Masahiko Taura and Takashi Nakagawa in Annals of Otology, Rhinology & Laryngology

Published
2019
Full Text
View/download PDF

45. Utility of negative‐pressure wound therapy for orocutaneous and pharyngocutaneous fistula following head and neck surgery

Author

Inatomi, Yusuke, primary, Kadota, Hideki, additional, Yoshida, Sei, additional, Kamizono, Kenichi, additional, Shimamoto, Ryo, additional, Fukushima, Seita, additional, Miyashita, Kayo, additional, Matsuo, Mioko, additional, Yasumatsu, Ryuji, additional, Tanaka, Shunichiro, additional, and Fukushima, Junichi, additional

Published
2019
Full Text
View/download PDF

46. Small Cell Carcinoma in the Head and Neck

Author

Wakasaki, Takahiro, primary, Yasumatsu, Ryuji, additional, Masuda, Muneyuki, additional, Matsuo, Mioko, additional, Tamae, Akihiro, additional, Kubo, Kazuhiko, additional, Kogo, Ryunosuke, additional, Uchi, Ryutaro, additional, Taura, Masahiko, additional, and Nakagawa, Takashi, additional

Published
2019
Full Text
View/download PDF

50. PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFRalteration and HPV infection in sinonasal squamous cell carcinoma

Author

Hongo, Takahiro, Yamamoto, Hidetaka, Jiromaru, Rina, Yasumatsu, Ryuji, Kuga, Ryosuke, Nozaki, Yui, Hashimoto, Kazuki, Matsuo, Mioko, Wakasaki, Takahiro, Tamae, Akihiro, Taguchi, Kenichi, Toh, Satoshi, Masuda, Muneyuki, Nakagawa, Takashi, and Oda, Yoshinao

Abstract

The antitumor efficacies of immune checkpoint inhibitors (ICIs) and the usefulness of potential predictive markers such as programmed death-ligand 1 (PD-L1) expression, density of tumor-infiltrating lymphocytes (TILs) and microsatellite instability (MSI) in sinonasal squamous cell carcinoma (SNSCC) have not been fully elucidated. We retrospectively analyzed 131 SNSCCs with immunohistochemistry for PD-L1 expression, TIL subpopulations and loss of mismatch repair (MMR) proteins as a surrogate for MSI-high. We also comprehensively evaluated the mutual relationships among these immuno-markers, high-risk human papillomavirus (HPV) infection, epidermal growth factor receptor(EGFR)gene status, and KRASmutation. PD-L1 expression (tumor proportion score ≥ 1%) was detected in 60 (45.8%) SNSCC cases and was significantly associated with worse overall survival (OS) (p= 0.0240). High density of cluster of differentiation 8 (CD8)-positive TILs was significantly associated with better progression-free survival (PFS) (p= 0.0368), and high density of forkhead box protein P3-positive TILs was significantly associated with better PFS and OS (p= 0.0007 and 0.0143, respectively). With respect to the combination of CD8 + TIL and PD-L1 expression, the high-CD8/PD-L1-negative group showed the most favorable prognosis, whereas the low-CD8/PD-L1-positive group showed the worst prognosis. MMR loss was detected in 3 (2.3%) of the 131 cases. HPV infection (6.1%), EGFRmutation (14.5%), EGFRcopy number gain (26%), and MMR loss were essentially mutually exclusive; patients in these molecular groups showed significant differences in prognosis but not in the degree of PD-L1 expression or TILs. Among the nine ICI-treated patients, three (33.3%) were responders, and the EGFR-wild type cases (n= 7) showed better clinical responses to an ICI compared to the EGFR-mutant cases (n= 2). Among the patients with residual/recurrent EGFR-wild type tumors (n= 43), ICI treatment significantly improved OS (p= 0.0281). The results suggest that the evaluation of immuno-markers and molecular subclassification may be helpful for prognostic prediction and selecting an individualized therapeutic strategy for patients with SNSCC.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results